BioCentury
ARTICLE | Company News

TapImmune, Marker Therapeutics merge

June 1, 2018 6:53 PM UTC

TapImmune (NASDAQ:TPIV) will merge with Marker Therapeutics Inc. (New Brighton, Minn.) to create a new cell therapy company. The merged company will use Marker Therapeutics's multi-antigen targeted cell therapy platform with TapImmune's peptide vaccine portfolio. The most advanced product in the combined pipeline, TPIV200, is a multi-epitope folate receptor 1 (FOLR1; FR-alpha) peptide vaccine in Phase II testing to treat ovarian cancer.

TapImmune said it will finalize a partnership with Baylor College of Medicine that includes sponsored research, manufacturing support and advancing early state clinical trials at the institution...